IL37 and inflammatory bowel disease: This notwithstanding, all currently available and approved therapies for IBD patients block the aberrant immunity only by dampening pro-inflammatory pathways, i.e., tumor necrosis factor (TNF)-α, gut-homing α4β7 integrin, interleukin (IL)-12/IL-23, and Janus kinases [3].